|
|
|
|
| LEADER |
01895nmm a2200433 u 4500 |
| 001 |
EB001902345 |
| 003 |
EBX01000000000000001065254 |
| 005 |
00000000000000.0 |
| 007 |
cr||||||||||||||||||||| |
| 008 |
201006 ||| eng |
| 100 |
1 |
|
|a Isaacs, John
|
| 245 |
0 |
0 |
|a Biologic therapy of rheumatoid arthritis
|h Elektronische Ressource
|c John Isaacs
|
| 260 |
|
|
|a London
|b Henry Stewart Talks
|c 2020, 2020
|
| 300 |
|
|
|a 1 streaming video file (40 min.)
|b color, sound
|
| 505 |
0 |
|
|a Contents: Pathology of rheumatoid arthritis -- Management of rheumatoid arthritis -- Biological therapies for rheumatoid arthritis -- TNF inhibitors, non-TNF inhibitors, and biosimilars -- Clinical trials for rheumatoid arthritis
|
| 653 |
|
|
|a Monoclonal antibodies
|
| 653 |
|
|
|a Arthritis, Rheumatoid / drug therapy
|
| 653 |
|
|
|a Rheumatoid arthritis / Alternative treatment
|
| 653 |
|
|
|a Drug Development
|
| 653 |
|
|
|a Rheumatoid arthritis / Chemotherapy
|
| 653 |
|
|
|a Antirheumatic Agents / therapeutic use
|
| 653 |
|
|
|a Biological Therapy
|
| 653 |
|
|
|a Biosimilar Pharmaceuticals
|
| 653 |
|
|
|a Clinical Trials as Topic
|
| 653 |
|
|
|a tocilizumab
|
| 653 |
|
|
|a Antibodies, Monoclonal
|
| 653 |
|
|
|a Rituximab
|
| 653 |
|
|
|a Synovial Membrane / pathology
|
| 653 |
|
|
|a Antirheumatic agents
|
| 653 |
|
|
|a Tumor Necrosis Factor Inhibitors
|
| 653 |
|
|
|a Tumor necrosis factor / Inhibitors
|
| 653 |
|
|
|a Drug development
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b HST
|a Henry Stewart Talks
|
| 490 |
0 |
|
|a Monoclonal antibodies as therapeutic agents : fundamentals, therapeutic applications and latest advances
|
| 500 |
|
|
|a Animated audio-visual presentation with synchronized narration. - Title from title frames. - Mode of access: World Wide Web
|
| 856 |
4 |
2 |
|u https://hstalks.com/bs/p/30
|3 Series
|
| 856 |
4 |
0 |
|u https://hstalks.com/bs/4295
|x Verlag
|z Streaming video file
|
| 082 |
0 |
|
|a 570
|